Peptide Therapeutics CDMO Market Size, Share, Growth and Forecast (2026 - 2036)

Peptide Therapeutics CDMO Market Analysis and Forecast by Fact.MR

According to Fact.MR estimates, the global peptide therapeutics cdmo market market was valued at USD 2.9 billion in 2025. The market is projected to reach USD 3.2 billion in 2026 and is expected to grow to USD 9.0 billion by 2036, expanding at a CAGR of 10.8%. Peptide API Manufacturing Services is anticipated to account for 42.0% of the product segment in 2026, while Oncology is expected to remain the leading application with around 34.0% share.

Summary of Peptide Therapeutics CDMO Market

• Market Snapshot
  • The Peptide Therapeutics CDMO market was valued at USD 2.9 billion in 2025.
  • By 2036, the Peptide Therapeutics CDMO market is expected to be worth USD 8.96 billion.
  • From 2026 to 2036, the market is projected to expand at a CAGR of 10.8%.
  • The market is projected to create an incremental opportunity of USD 5.75 billion between 2026 and 2036.
  • In 2026, Peptide API Manufacturing Services are expected to account for 42% of the service segment, driven by surging demand for GLP-1 class peptides, increased complexity of long-chain peptides, and sponsor preference for outsourced solid-phase peptide synthesis capacity.
  • India (15.8%) and China (14.2%) are two of the fastest-growing markets in the world.
• Demand and Growth Drivers
  • Demand is shaped by the unprecedented commercial success of GLP-1 peptide therapeutics, led by semaglutide, tirzepatide, and the next wave including retatrutide, which has created structural capacity shortages across global solid-phase peptide synthesis infrastructure.
  • Growth reflects sponsor preference for outsourced peptide manufacturing because SPPS capacity is capital-intensive, requires specialized reactors and purification infrastructure, and benefits from the scale economics that only dedicated CDMOs can achieve.
  • Adoption is increasing due to the rising complexity of therapeutic peptides, including longer chain lengths, non-standard amino acids, lipidation and PEGylation chemistry, and complex conjugation steps that favor experienced CDMO partners over in-house manufacturing.
• Product and Segment View
  • Peptide API Manufacturing Services lead the service segment at 42% share in 2026, anchored by commercial-scale solid-phase peptide synthesis capacity serving approved and late-stage GLP-1 and metabolic disease peptides.
  • Pharmaceutical Companies represent the majority of end-user demand in 2026, reflecting concentrated procurement by large pharma sponsors with approved peptide products requiring high-volume commercial supply, along with biotech sponsors running clinical-stage peptide programs.
  • Solid-phase peptide synthesis dominates the technology segment in 2026, with liquid-phase and hybrid synthesis platforms used selectively for specific peptide classes and scale requirements.
• Geography and Competitive Outlook
  • Asia Pacific leads growth, with India at a 15.8% CAGR supported by expanding CDMO capacity from Piramal Pharma Solutions, Auro Peptides, and domestic capacity additions, and China at 14.2% anchored by WuXi AppTec and expanding domestic peptide manufacturing.
  • Europe contributes strongly through established leaders, with Switzerland at a 10.1% CAGR anchored by Bachem and Lonza, and Germany (10.8%) supported by CordenPharma, Wacker Chemie, and Fresenius Kabi.
  • North America grows at a slower pace, with the United States at a 9.6% CAGR, reflecting mature sponsor demand and selective CDMO capacity expansion. Leading players include Bachem, Lonza Group, Polypeptide Group, AmbioPharm, CordenPharma, CPC Scientific, WuXi AppTec, Fresenius Kabi, Piramal Pharma Solutions, and Almac.
• Analyst Opinion
  • Peptide therapeutics CDMO has moved from a steady specialty manufacturing niche to one of the most commercially attractive and capacity-constrained segments in biopharma contract manufacturing. The demand surge is driven almost entirely by GLP-1 peptides, where semaglutide, tirzepatide, and the next-wave candidates have created order volumes that substantially exceed historical peptide manufacturing capacity. CDMOs with established SPPS infrastructure are booking multi-year commercial supply contracts at premium economics, and new capacity additions are being absorbed before they come online. The strategic question for sponsors is whether to lock in long-term capacity commitments now or pursue partial in-house manufacturing to reduce supply risk. The strategic question for CDMOs is whether to compete on volume capacity, on complex peptide chemistry capability, or on integrated sterile fill-finish services. Firms combining SPPS scale with complex chemistry depth and integrated fill-finish will set the pricing and service benchmarks over the forecast period.

Why is the Peptide Therapeutics CDMO Market Growing?

• GLP-1 peptide therapeutics have created a structural demand shock for peptide CDMO capacity, with semaglutide, tirzepatide, and retatrutide driving order volumes that substantially exceed pre-2022 global SPPS infrastructure.
• Sponsor outsourcing preferences favor specialized peptide CDMOs because in-house SPPS capacity requires specialized reactors, purification trains, amino acid supply relationships, and dedicated cGMP regulatory infrastructure that most sponsors cannot justify for single-program programs.
• Rising peptide complexity, including longer chains, non-standard amino acids, lipidation and PEGylation chemistry, and complex conjugation steps, is increasing per-kilogram service value and driving sponsor preference for experienced CDMO partners.

GLP-1 demand is the primary demand engine. Semaglutide and tirzepatide sales growth has been unprecedented in biopharma, and both molecules require high-volume peptide API at commercial scale. Retatrutide and other next-wave GLP-1 or GIP-GLP-1-glucagon triagonist candidates in clinical development represent additional demand waves that will continue scaling across the forecast period. Each approved or late-stage GLP-1 program generates multi-year commercial supply contracts at premium economics, and global SPPS capacity has been insufficient to meet demand even after substantial capacity expansion announcements.

Outsourcing economics are the second driver. Building in-house peptide manufacturing requires a multi-hundred-million-dollar investment in specialized SPPS reactors, HPLC purification trains, amino acid and resin supply relationships, sterile fill-finish infrastructure, and cGMP regulatory expertise. For most biopharma sponsors, particularly those with one or two peptide programs in their pipeline, that investment does not generate acceptable returns. Specialized peptide CDMOs spread that infrastructure across multiple sponsor programs, which makes the unit economics work and creates structural preference for outsourced peptide supply.

Chemistry complexity is the third driver. Therapeutic peptides are getting longer, with 30-plus amino acid backbones, complex lipidation patterns, PEG conjugations, and cyclization steps that require experienced manufacturing expertise. Each step of chemistry complexity increases the per-kilogram service value and raises the barrier to in-house manufacturing, which strengthens the CDMO value proposition over the forecast period.

Segment-wise Analysis of Peptide Therapeutics CDMO Market

• Peptide API Manufacturing Services lead the service segment at 42% share in 2026, driven by commercial-scale SPPS capacity serving approved and late-stage GLP-1 and metabolic disease peptides.
• GLP-1 and metabolic disease peptides dominate the therapeutic class segment in 2026, reflecting the unprecedented commercial success of semaglutide and tirzepatide and the depth of the late-stage pipeline.
• Solid-phase peptide synthesis leads the technology segment in 2026, with liquid-phase and hybrid synthesis platforms used selectively for short peptides, specific conjugations, and selected production scales.

The peptide therapeutics CDMO market segments across service type, peptide class, end use, technology, distribution channel, and packaging. Service type coverage includes peptide API manufacturing, process development and scale-up, sterile fill-finish, analytical and quality control, and integrated end-to-end services. Peptide class coverage spans GLP-1 agonists and metabolic disease peptides, oncology peptides, antimicrobial peptides, peptide vaccines, and specialty peptides. Technology coverage includes solid-phase peptide synthesis, liquid-phase peptide synthesis, hybrid synthesis, and chemoenzymatic approaches.

Peptide API Manufacturing Leads the Service Segment

Peptide API manufacturing services account for 42% of service revenue in 2026. The subsegment is anchored by commercial-scale SPPS capacity dedicated to GLP-1 peptides, by process development and scale-up services supporting clinical-stage programs moving toward approval, and by high-complexity manufacturing for lipidated and conjugated peptides. Multi-year commercial supply contracts with GLP-1 sponsors are the single largest revenue pool within the service segment.

Sterile fill-finish services and analytical characterization represent the second and third largest service subsegments. Integrated CDMOs that offer end-to-end services from API manufacturing through fill-finish are capturing premium service economics because they reduce supply chain complexity for sponsors. Analytical services are growing as peptide complexity rises, because longer and more complex peptides require more sophisticated characterization and release testing.

GLP-1 Peptides Dominate the Therapeutic Class Segment

GLP-1 agonists and metabolic disease peptides together represent the largest therapeutic class in 2026. Semaglutide and tirzepatide drive the current commercial demand, with retatrutide and other late-stage candidates providing a pipeline of additional high-volume programs. The therapeutic class is uniquely attractive for CDMOs because individual programs generate very high API volumes over long commercial horizons, which creates predictable capacity utilization and strong economic returns.

Oncology peptides form a second therapeutic class pool, covering peptide-drug conjugates, tumor-targeting peptides, and peptide vaccines in cancer indications. Antimicrobial peptides, cardiovascular peptides, and specialty peptide classes represent smaller but strategically important pools. The therapeutic class mix will continue tilting toward metabolic disease through the forecast period as additional GLP-1 and related programs reach commercial approval.

Key Growth Drivers, Constraints, and Market Scope

• GLP-1 demand surge, sponsor outsourcing economics, and rising peptide chemistry complexity are creating structural demand growth across the forecast period.
• SPPS capacity constraints, specialty amino acid and resin supply bottlenecks, and skilled peptide chemistry workforce shortages constrain the pace at which supply can match demand.
• Expansion opportunities exist in Asia Pacific, particularly India and China, where capacity additions are absorbing overflow demand from constrained Western CDMO infrastructure.

The peptide therapeutics CDMO market is at a structural inflection point. Demand fundamentals are exceptionally strong, supply is constrained, and capacity expansion plans are being announced and built across major regions. The key variables over the forecast period are the pace of new SPPS capacity coming online, the entry of additional GLP-1 and next-wave candidates into commercial supply, and specialty amino acid and resin supply chain resilience.

Growth Drivers

Three primary forces drive growth. First, GLP-1 peptide therapeutic demand has created a structural capacity shortage that supports premium CDMO economics and drives multi-year capacity expansion programs. Second, sponsor outsourcing economics favor specialized peptide CDMOs because the capital intensity, specialized expertise, and regulatory infrastructure required for in-house SPPS manufacturing cannot be justified by most sponsors running single programs. Third, rising peptide chemistry complexity, including longer chains, non-standard amino acids, lipidation and conjugation steps, increases per-kilogram service value and raises the competitive barrier for new entrants.

Constraints

SPPS capacity is the most significant constraint on near-term growth. Building new peptide manufacturing capacity requires 24 to 36 months of construction and qualification time, which means near-term supply is structurally constrained even with aggressive capacity expansion programs. Specialty amino acid supply, particularly for non-standard amino acids used in complex peptide synthesis, is concentrated among a small number of suppliers and can become a bottleneck when demand surges. Skilled peptide chemistry workforce is in short supply, because peptide synthesis requires specialized training that is not broadly available. Regulatory complexity around GMP peptide manufacturing, particularly for new facility qualifications, extends timelines and adds cost.

Opportunities

The largest near-term opportunity is in commercial-scale GLP-1 API supply, where CDMOs with available SPPS capacity can book long-dated supply contracts at premium economics. A second opportunity is in Asia Pacific capacity expansion, particularly India and China, where lower cost structures and aggressive capacity additions are capturing demand overflow from constrained Western CDMOs. A third opportunity is in complex peptide chemistry, where CDMOs with expertise in lipidation, PEGylation, cyclization, and conjugation can command premium pricing for differentiated services. Integrated service offerings that combine peptide API manufacturing with sterile fill-finish and analytical services capture additional value per program and create customer stickiness.

Regional Outlook Across Key Markets

• Asia Pacific leads growth, with India at a 15.8% CAGR anchored by expanding capacity at Piramal Pharma Solutions, Auro Peptides, and domestic CDMO additions, and China (14.2%) supported by WuXi AppTec and domestic peptide capacity programs.
• South Korea (12.9%) and Japan (11.7%) grow steadily, supported by domestic CDMO capacity additions and established biopharma peptide programs.
• Europe contributes strongly through established leaders, with Germany (10.8%), Switzerland (10.1%), and continued Lonza, Bachem, and Polypeptide expansion programs.
• North America grows more slowly, with the United States at a 9.6% CAGR, reflecting mature sponsor demand and selective CDMO capacity expansion.

Regional performance reflects both the geography of established peptide CDMO leaders and the geographic pattern of capacity expansion. Asia Pacific leads growth because lower cost structures and aggressive capacity addition programs are capturing demand that cannot be served by constrained Western infrastructure. Europe remains the historical center of peptide manufacturing expertise through Bachem, Polypeptide Group, Lonza, and CordenPharma, but growth rates are slower because the installed base is already large. North America has a substantial installed base at AmbioPharm, Polypeptide, and other firms but grows more slowly than Asia Pacific from a mature baseline.

India

India is the fastest-growing major market, with a 15.8% CAGR through 2036. The country hosts Piramal Pharma Solutions, Auro Peptides, and multiple domestic CDMOs building peptide manufacturing capacity, and is increasingly capturing commercial-scale GLP-1 and complex peptide manufacturing demand. Hyderabad, Mumbai, and Bengaluru are the primary manufacturing centers. Government pharma export promotion programs and competitive labor and construction costs support aggressive capacity expansion.

• Piramal Pharma Solutions, Auro Peptides, and domestic CDMOs are scaling peptide manufacturing capacity aggressively.
• Hyderabad, Mumbai, and Bengaluru are the primary peptide CDMO manufacturing centers.
• Government pharma export promotion, competitive costs, and skilled chemistry workforce support rapid capacity expansion.

China

China records a 14.2% CAGR through 2036. WuXi AppTec anchors domestic peptide CDMO leadership, and additional Chinese CDMOs are building peptide-specific manufacturing capacity to serve domestic and export demand. Shanghai, Suzhou, and Tianjin are the primary manufacturing centers. Domestic biopharma demand for peptide therapeutics is growing rapidly, supporting sustained local CDMO growth alongside export-oriented capacity.

• WuXi AppTec anchors Chinese peptide CDMO leadership with substantial SPPS capacity and integrated services.
• Shanghai, Suzhou, and Tianjin are the primary peptide CDMO manufacturing centers.
• Growing domestic biopharma peptide pipeline demand supports sustained local CDMO growth alongside export manufacturing.

South Korea

South Korea posts a 12.9% CAGR through 2036. Samsung Biologics and Korean peptide-focused CDMOs are building peptide capacity to serve global biopharma sponsors and a growing domestic biotech pipeline. Government bio-innovation programs direct substantial public funding into CDMO capacity development, and Seoul and Incheon are the primary manufacturing centers.

• Samsung Biologics and peptide-focused Korean CDMOs are scaling capacity to serve global and domestic peptide demand.
• Government bio-innovation programs direct public funding into CDMO capacity development and peptide manufacturing expansion.
• Seoul and Incheon biocluster infrastructure supports peptide CDMO expansion and operations.

Japan

Japan records an 11.7% CAGR through 2036. Established domestic CDMOs serve Japanese pharma sponsors in diabetes, oncology, and cardiovascular peptide programs, and Takeda, Daiichi Sankyo, and Astellas anchor domestic peptide therapeutic pipelines. PMDA regulatory engagement on peptide therapeutics is well-developed, supporting efficient clinical and commercial translation.

• Established Japanese peptide CDMOs serve domestic sponsors across diabetes, oncology, and cardiovascular indications.
• Takeda, Daiichi Sankyo, and Astellas anchor domestic peptide therapeutic pipelines and CDMO demand.
• PMDA regulatory engagement on peptide therapeutics is mature and supports efficient clinical and commercial translation.

Germany

Germany posts a 10.8% CAGR through 2036. CordenPharma and Wacker Chemie anchor German peptide CDMO capability, with additional capacity from Fresenius Kabi and specialty CDMOs serving commercial peptide supply. Frankfurt, Cologne, and Munich biotech and pharma clusters support peptide CDMO operations.

• CordenPharma and Wacker Chemie anchor German peptide CDMO capability with substantial installed SPPS capacity.
• Fresenius Kabi and specialty CDMOs provide additional peptide manufacturing capacity serving commercial supply.
• Frankfurt, Cologne, and Munich biotech and pharma clusters support peptide CDMO operations and workforce.

Switzerland

Switzerland records a 10.1% CAGR through 2036. Bachem anchors global peptide CDMO leadership from its Bubendorf facility, and Lonza's Visp peptide operations provide substantial additional commercial capacity. The country's concentrated pharma and biotech ecosystem, high-quality workforce, and established regulatory infrastructure support premium peptide CDMO economics.

• Bachem anchors global peptide CDMO leadership from its Bubendorf facility with substantial commercial SPPS capacity.
• Lonza's Visp peptide operations provide additional commercial-scale peptide manufacturing capacity.
• Concentrated pharma and biotech ecosystem and skilled workforce support premium peptide CDMO economics.

United States

The United States posts a 9.6% CAGR through 2036. AmbioPharm and Polypeptide Laboratories anchor US peptide CDMO capability, with additional capacity from specialty CDMOs serving clinical and commercial supply. FDA regulatory engagement on peptide therapeutics is mature, and the country hosts substantial sponsor pipeline demand for peptide therapeutic programs.

• AmbioPharm and Polypeptide Laboratories anchor US peptide CDMO capability with established SPPS capacity.
• FDA regulatory engagement on peptide therapeutics is mature and supports efficient clinical and commercial translation.
• Substantial US sponsor pipeline demand for peptide therapeutics drives consistent CDMO utilization.

Competitive Benchmarking and Company Positioning

• Bachem, Lonza, and Polypeptide Group collectively represent the historical core of the peptide CDMO category, supported by decades of SPPS expertise, commercial-scale capacity, and established sponsor relationships.
• Asia Pacific CDMOs led by WuXi AppTec and Piramal Pharma Solutions are rapidly gaining share through aggressive capacity expansion and competitive cost structures.
• Specialty and integrated CDMOs including CordenPharma, CPC Scientific, AmbioPharm, Fresenius Kabi, and Almac participate with differentiated capability in complex chemistry, sterile fill-finish, or integrated end-to-end services.

The peptide therapeutics CDMO market features a clear tier structure. Bachem, Lonza, and Polypeptide Group form the leadership tier through decades of SPPS scale expertise and long-term sponsor relationships. WuXi AppTec and major Asia Pacific CDMOs form a rapidly rising second tier through aggressive capacity expansion and competitive cost economics. Specialty CDMOs form a third tier, competing on complex chemistry, sterile fill-finish integration, or regional service. Competitive positions will shift through the forecast period as capacity expansion programs come online and sponsor preferences on supply diversification influence CDMO selection.

Bachem holds estimated 22% share in 2026, anchored by its Bubendorf facility and long-term GLP-1 and peptide therapeutic supply contracts. Lonza, through its Visp peptide operations, holds a strong second position with integrated small-molecule and peptide capacity. Polypeptide Group maintains substantial capacity across multiple global sites. AmbioPharm in the United States is a significant specialty player with deep GLP-1 manufacturing expertise.

CordenPharma, CPC Scientific, Fresenius Kabi, Wacker Chemie, and Almac participate with differentiated service offerings. CordenPharma offers strong integrated small-molecule and peptide services across multiple European facilities. CPC Scientific provides specialty peptide chemistry and complex peptide manufacturing. WuXi AppTec has emerged as a significant peptide player through aggressive capacity expansion serving global demand. Piramal Pharma Solutions and Auro Peptides are scaling rapidly in India, capturing commercial supply demand that cannot be served by constrained Western CDMOs.

The competitive dynamics favor firms with three attributes: commercial-scale SPPS capacity, complex peptide chemistry capability, and integrated sterile fill-finish services. Bachem and Lonza lead on scale and integrated services. WuXi AppTec and Piramal lead on cost-competitive expansion. CordenPharma and CPC Scientific lead on specialty chemistry. Commercial winners over the next decade will combine scale, complex chemistry, and integrated services while managing capacity expansion investment risk carefully as multiple large programs compete for limited infrastructure.

Competitive Analysis

Strategic positioning is shaped by the choice between scale and specialty differentiation. Leading CDMOs with commercial-scale SPPS capacity and long-term sponsor relationships capture the largest GLP-1 and metabolic disease peptide volumes. Specialty CDMOs with complex chemistry expertise capture higher per-kilogram economics for differentiated peptide classes. Integrated CDMOs offering end-to-end API through fill-finish services capture additional value and customer stickiness. Capacity expansion investment decisions are the dominant strategic question, because building new SPPS infrastructure is capital-intensive and multi-year, and CDMOs must balance commercial demand visibility against the risk of capacity overhang if GLP-1 or other peptide programs miss expectations.

Benchmarking Table

Recent Developments

• Bachem announced multi-hundred-million-dollar capacity expansion at its Bubendorf and Sisseln facilities in 2025, adding substantial SPPS capacity and sterile fill-finish infrastructure to serve GLP-1 and peptide therapeutic demand.
• Lonza expanded peptide manufacturing capacity at its Visp, Switzerland site in 2025, adding commercial-scale SPPS infrastructure and integrated services to serve long-term peptide supply contracts.
• Polypeptide Group announced capacity expansion across multiple global sites in 2025 and 2026, responding to sustained commercial peptide demand and locking in multi-year sponsor supply agreements.

Leading Companies Shaping Peptide Therapeutics CDMO Market

• Major Players

  • Bachem
  • Lonza Group
  • Polypeptide Group
  • AmbioPharm
  • CordenPharma
  • WuXi AppTec
  • Piramal Pharma Solutions

• Emerging Players

  • CPC Scientific
  • Fresenius Kabi
  • Almac
  • Wacker Chemie
  • PolyPeptide Laboratories
  • Auro Peptides
  • Samsung Biologics
  • Catalent
  • Thermo Fisher Scientific
  • Siegfried

Sources and Research References

• World Health Organization (WHO) essential medicines and peptide therapeutic publications
• U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research peptide therapeutic guidance and approval data
• European Medicines Agency (EMA) guidelines on peptide active substances and peptide drug products
• Bachem, Lonza Group, Polypeptide Group, WuXi AppTec, AmbioPharm, CordenPharma, and Piramal Pharma Solutions corporate filings and investor presentations
• FDA Orange Book and approved peptide therapeutic pipeline data
• Peer-reviewed peptide manufacturing and therapeutic journals including Journal of Peptide Science, Molecular Pharmaceutics, and Organic Process Research and Development
• Trade publications including Pharmaceutical Technology, Contract Pharma, and BioPharma Reporter
• Primary interviews with CDMO executives, biopharma manufacturing and supply chain leaders, specialty amino acid suppliers, and regulatory affairs professionals

This bibliography is provided for reader reference and is not exhaustive. The full report contains the complete reference list and detailed citations.

Key Questions This Report Addresses

• What is the size of the peptide therapeutics CDMO market in 2026 and 2036?
• What CAGR is the market expected to record between 2026 and 2036?
• Which service and technology segments are projected to lead the market in 2026?
• Which therapeutic peptide class accounts for the largest share of CDMO demand?
• How are GLP-1 peptides reshaping global SPPS capacity and CDMO economics?
• Which countries are the fastest-growing markets through 2036?
• Who are the leading companies in peptide CDMO manufacturing, and how are they competitively differentiated?
• How does Fact.MR estimate and validate the market forecast?

Peptide Therapeutics CDMO Market Definition

The peptide therapeutics CDMO market covers contract development and manufacturing services for peptide active pharmaceutical ingredients, peptide drug products, and related analytical and release activities delivered by specialized contract organizations to pharmaceutical and biotechnology sponsors. The scope includes peptide API manufacturing via solid-phase peptide synthesis, liquid-phase peptide synthesis, and hybrid approaches, along with peptide drug product formulation, sterile fill-finish services, lyophilization, analytical characterization, stability testing, and cGMP release testing.

Peptide Therapeutics CDMO Market Inclusions

The market includes peptide API manufacturing services across chain lengths and complexity levels, including short peptides, medium and long peptides, lipidated peptides, PEGylated peptides, cyclic peptides, and peptide conjugates. It covers process development and scale-up services, clinical-scale and commercial-scale cGMP manufacturing, sterile fill-finish services for peptide drug products, analytical characterization, stability testing, and peptide-specific QC and release services. Work done for GLP-1 agonists, metabolic disease peptides, oncology peptides, antimicrobial peptides, and peptide vaccines is in scope.

Peptide Therapeutics CDMO Market Exclusions

The market excludes internal peptide manufacturing done by biopharma sponsors in their own facilities, merchant peptide reagent supply outside of contract manufacturing engagements, and small-scale research peptide synthesis not tied to therapeutic program development. Generic sterile fill-finish services not associated with peptide drug products, therapeutic revenue for the sponsor brand, and unrelated small-molecule API CDMO work are also excluded. Academic research peptide services and bench-scale peptide synthesis without cGMP deliverables fall outside the scope.

Peptide Therapeutics CDMO Market Research Methodology

• Primary Research: Interviews with CDMO business development and operations leads at leading peptide manufacturers, biopharma manufacturing and supply chain executives running active peptide programs, specialty amino acid and resin suppliers, and regulatory affairs professionals specializing in peptide therapeutics.
• Desk Research: Peptide therapeutic pipeline databases, FDA and EMA approval records for peptide products, CDMO capacity expansion announcements, annual reports of Bachem, Lonza, Polypeptide Group, WuXi AppTec, and Piramal Pharma Solutions, and peer-reviewed peptide manufacturing literature.
• Market Sizing: Demand-side model built on active clinical and commercial peptide programs, estimated per-kilogram SPPS manufacturing costs and contract values, CDMO capacity utilization across peptide-specific infrastructure, and commercial supply contract pricing benchmarks for GLP-1 and adjacent peptide classes.
• Data Validation: Triangulated across CDMO reported peptide segment revenues, sponsor pipeline disclosures, capital expenditure announcements tied to peptide capacity, and primary interviews. Sensitivity testing on capacity utilization, pricing, and commercial-to-clinical program mix.